Patent · US Active

Humanized anti-CXCR5 antibodies, derivatives thereof and their use

US8980262B2 · kind B2 · utility

0Cited by

72References

23Claims

0Family size

Assignee

Sanofi · FR

Inventors

Renata Lee · Edison, US
Vincent Mikol · Charenton-le-Pont, FR
Elizabeth Allen · Stewartsville, US
Norman Ruetsch · Moorestown, US
Beatrice Cameron · Paris, FR
Thomas Oligino · Easton, US
Nicholas Baurin · Arpajon, FR

Key dates

Filing date	Mar 11, 2013
Grant date	Mar 17, 2015
Priority date	—
Expiry date	Mar 11, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.